The purpose of this study is to test whether carvedilol can reduce the occurrence of heart problems during your cancer treatment. Carvedilol (Coreg®) is a medication that is FDA approved and used to treat congestive heart failure and high blood pressure and is not a new medication. It has been shown in small studies to protect the heart from side effects of chemotherapies such as doxorubicin (Adriamycin®) and trastuzumab (Herceptin®). The effects of carvedilol will be compared to the usual approach. Previously, people who were already taking a beta blocker, angiotensin receptor blocker (ARB), or angiotensin converting enzyme (ACE) inhibitor were able to take part in the study. The study has reached the maximum number of people allowed who are already on those treatments now, so, you must not be taking these types of drugs in order to be part of the study. There will be about 817 people taking part in this study.

The purpose of this study is to test whether carvedilol can reduce the occurrence of heart problems during your cancer treatment. Carvedilol (Coreg®) is a medication that is FDA approved and used to treat congestive heart failure and high blood pressure and is not a new medication. It has been shown in small studies to protect the heart from side effects of chemotherapies such as doxorubicin (Adriamycin®) and trastuzumab (Herceptin®). The effects of carvedilol will be compared to the usual approach. Previously, people who were already taking a beta blocker, angiotensin receptor blocker (ARB), or angiotensin converting enzyme (ACE) inhibitor were able to take part in the study. The study has reached the maximum number of people allowed who are already on those treatments now, so, you must not be taking these types of drugs in order to be part of the study. There will be about 817 people taking part in this study.

To see how ziltivekimab taken once monthly versus placebo, both added to standard of care, in reducing the risk of cardiovascular death and heart failure events in participants with heart failure iwht mildly reduced or preserved ejection fraction and systemic inflammation.

Return for on site visits 14 times, participate in 6 phone calls, complete questionnaires, blood samples taken at each on-site visit, electrocardiogram completed on 5 visits, injection of study medication.

approximatley $1,120

The purpose of this voluntary research study is to collect measurements of related heart function using an insertable cardiac monitor (ICM) in heart failure patients. Commercially available ICMs are used for the detection of abnormal heart rhythms and long-term monitoring. The ICM does not provide therapy, but for this study has various sensors which offer added heart failure diagnostic features. Patients will be required to undergo the investigational implantable cardiac defibrillator, attend 6 clinical visits, agree to wear a mobile monitor which is similar to a cell phone with a downloaded application named myLUX, tell the study doctor if any planned or unplanned visits to the hospital for any reason, admission to the hospital for heart failure, and/or if they have been treated with an IV medication for heart failure in the emergency room, urgent care or clinic.

The purpose of this voluntary research study is to collect measurements of related heart function using an insertable cardiac monitor (ICM) in heart failure patients. Commercially available ICMs are used for the detection of abnormal heart rhythms and long-term monitoring. The ICM does not provide therapy, but for this study has various sensors which offer addedheart failure diagnostic features. You will be required to undergo the investigational implantable cardiac defibrillator, attend 6 clinical visits, agree to wear a mobile monitor which is similar to a cell phone with a downloaded application named myLUX, tell your study doctor if you have any planned or unplanned visits to the hospital for any reason, admission to the hospital for heart failure, and/or if you have been treated with an IV medication for your heart failure in the emergency room, urgent care or your clinic.

$250